- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Robbins LLP Informs Investors of Aldeyra Therapeutics Class Action
Law firm notifies shareholders of pending lawsuit against biotech company.
Mar. 31, 2026 at 12:30pm
Got story updates? Submit your updates here. ›
A legal case against a biotech firm exposes the financial and reputational risks facing the industry.San Diego TodayRobbins LLP, a national shareholder rights litigation firm, has informed investors of a pending class action lawsuit against Aldeyra Therapeutics, Inc. The lawsuit alleges the company made false and misleading statements about the development and prospects of its lead drug candidate, reproxalap, which is being evaluated for the treatment of dry eye disease.
Why it matters
Shareholder class actions can have significant financial and reputational impacts on public companies, especially in the highly competitive and regulated biotech industry. The outcome of this lawsuit could affect investor confidence and Aldeyra's ability to raise future funding for its drug pipeline.
The details
The class action lawsuit was filed in the U.S. District Court for the District of New Jersey on behalf of investors who purchased Aldeyra securities between March 11, 2022 and November 9, 2025. The complaint alleges that Aldeyra and its executives misled investors about the efficacy and commercial viability of reproxalap, causing the company's stock price to be artificially inflated.
- The class action lawsuit was filed on March 31, 2026.
- The lawsuit covers the period from March 11, 2022 to November 9, 2025.
The players
Robbins LLP
A national shareholder rights litigation firm that has filed the class action lawsuit against Aldeyra Therapeutics.
Aldeyra Therapeutics, Inc.
A biotechnology company developing novel therapies for immune-mediated diseases, including dry eye disease.
What’s next
The court will now consider the merits of the case and determine whether to certify the class of affected investors.
The takeaway
This lawsuit highlights the risks and challenges facing biotech companies as they navigate the complex regulatory environment and strive to bring new treatments to market. Investors will be closely watching the outcome, which could have broader implications for the industry.
